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Summary Erythropoietic protoporphyria (EPP) is a
rare hereditary disorder due to a partial deficiency of
ferrochelatase (FECH). The genotype of EPP patients
features a mutation on one allele of the FECH gene
and a common hypomorphic FECH IVS3–48c on the
other allele (M/c). The resulting enzyme activity in
patients is õ35% of that in normal individuals.
Ferrochelatase deficiency results in the accumulation
of protoporphyrin in the skin, which is responsible for
the clinical symptom of cutaneous photosensitivity in
patients. In this study, we report the identification of a
novel FECH mutation delT23 in an 11-member EPP
family of Jewish origin. Two EPP siblings shared an
identical genotype of delT23/IVS3–48c (M/c). They
were both photosensitive and showed highly increased
erythrocyte protoporphyrin. The genotype of the
patients_ mother, who did not present with any EPP
clinical symptoms, was delT23/IVS3–48t (M/t). The
patients_ father, an offspring of consanguineous
parents, was homozygous IVS3–48 c/c. He exhibited a
mild photosensitivity, and an increase of 4-fold in
erythrocyte protoporphyrin. His FECH mRNA
amount was 71% of that of genotype t/t. It is the first
reported case of an individual with c/c genotype who
exhibits both biochemical and clinical indications of
EPP. These results suggest that IVS3–48c is a func-
tional variant of ferrochelatase. The clinical symptoms
and biochemical abnormalities in the patients_ father
could be the result of an interaction between genetic
and environmental factors. In addition, the frequency
of IVS3–48c in the Ashkenazi Jewish population was
estimated at 8%, which is similar to that in the
European populations.
Abbreviations
EPP erythropoietic protoporphyria
FECH ferrochelatase
PCR polymerase chain reaction
RBC red blood cells
SNP single nucleotide polymorphism
Introduction
Erythropoietic protoporphyria (EPP, OMIM #177000)
is a hereditary disorder of the haem biosynthetic
pathway. The affected enzyme ferrochelatase (FECH,
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EC 4.99.1.1) catalyses the insertion of iron into
protoporphyrin IX to form haem. As the result of
ferrochelatase deficiency, a large amount of protopor-
phyrin accumulates in the skin, which is responsible for
the clinical symptoms of photosensitivity in EPP
patients (Anderson et al 2001). In addition to the
cutaneous symptoms, EPP-related liver failure occurs
in about 1% of the patients (Holme et al 2006). EPP is
transmitted as an autosomal dominant trait in >97% of
the cases, or as an autosomal recessive trait. In the
dominant inheritance, which occurs in the majority of
the families, the clinical expression of EPP requires a
deleterious mutation on one allele of the FECH gene
and a common SNP IVS3–48c on the other allele
(M/c). The frequencies of IVS3–48c vary from popu-
lation to population. The highest frequency found so
far, 45%, was in the Japanese population and the
lowest, less than 1%, among black Africans (Gouya
et al 2006; Nakano et al 2006).
To date, a total of 109 mutations have been
described in the FECH gene of EPP families (HGMD,
accessed in March 2008). In this study, we report
biochemical and genetic characterization of EPP in an
Ashkenazi Jewish family in which the father was an
offspring of consanguineous parents.
Material and methods
Subjects and biochemical analyses
An 11-member Ashkenazi family of three generations
was studied (Fig. 1). The index patient, a 36-year-old
woman and her 26-year-old brother, have suffered
from skin photosensitivity since early childhood. They
were diagnosed as EPP patients at the ages of 24 and
14 years, respectively. The diagnosis was established in
both on the basis of highly increased erythrocyte
protoporphyrin and a distinct peak in the plasma
emission scan at 635 nm (Table 1). As shown in the
table, both exhibited increased faecal protoporphyrin.
Normal faecal coproporphyrin (15 and 25 mg/g dry
weight, respectively) and a ratio of 0.3 of copropor-
phyrin III/I (normal <1) were measured in both of
them (not shown). So far, the patients have exhibited
normal liver function. The father of the index patient,
who was an offspring of consanguineous parents,
suffered from mild symptoms of photosensitivity. He
experienced a feeling of itching and burning in the skin
shortly after sun exposure. He has tried to avoid the
sun throughout his life. Repeated measurements
showed 3- to 4-fold increases in erythrocyte protopor-
phyrin concentration. A slight increase in erythrocyte
protoporphyrin concentration was observed also in the
mother as well as in the eldest son of the index patient
(Table 1). The rest of the family members were not
tested biochemically. None of them showed clinical
signs of EPP.
Fifty non-porphyric individuals of Jewish origin
(Ashkenazi), three non-porphyric caucasians with
genotypes t/t, c/t and c/c at IVS3–48 in the FECH
gene, respectively, as well as an EPP patient from an
unrelated family (genotype M/c), were recruited into
the study. Informed consent was obtained from all
subjects. This study was approved by the Helsinki
committee of the Israeli Ministry of Health.
Plasma fluorescence emission scanning was carried
out according to Long et al (1993). Erythrocyte free
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Fig. 1 Pedigree of an Ashkenazi EPP family. Solid symbols
represent EPP patients with the genotype M/c and the open
symbols represent individuals with genotype M/t. The index
patient is indicated by an arrow. The FECH alleles are illustrated
below the symbol of each individual. The mutated allele is
highlighted in red and the low-expressed allele (IVS3–48c) in
orange. wt, wild type; M, mutation delT23. The presence/absence
of mutation delT23 is indicated by F+/j_
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protoporphyrin was measured according to the method
of Piomelli (1973), modified as previously described
(Schoenfeld et al 2003). Faecal porphyrins were
extracted according to With (1978) and separated by
HPLC according to Lim and Peters (1984).
Mutational analysis
Peripheral blood samples were collected from all
subjects. Genomic DNA was isolated from peripheral
blood using the QIAamp Blood Kit (Qiagen, Hilden,
Germany). The 11 coding exons of the FECH gene,
along with 52–191 bp of their flanking regions, were
amplified by PCR using specific primers. Sequence
analysis was performed on the ABI Prism 310 genetic
analyser (Applied Biosystems, Foster City, CA, USA).
Sequence analysis of genomic DNA also revealed the
status of SNP IVS3–48c/t in the subjects.
Preparation of cDNA
For preparation of cDNA, a separate blood sample
was collected from the subjects concerned in a PAX-
gene Blood RNA tube (Qiagen). Total RNA was
isolated by using the PAXgene Blood RNA Validation
Kit (Qiagen). An aliquot of total RNA was analysed on
an Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA,
USA) using the Eukaryote Total RNA Nano Kit. The
quality of total RNA was evaluated by both the 28S/18S
ratio and RIN (RNA integrity number). mRNA (1 mg
of total RNA) was reverse-transcribed into cDNA by
using the First Strand cDNA Synthesis Kit (Roche,
Basel, Switzerland).
Real-time PCR quantification of FECH cDNA
Real-time PCR quantification of ferrochelatase cDNA
was performed on an ABI Prism 7000 Sequence
Detection System (Applied Biosystems). b-Actin was
used as an endogenous control. Reagents used for real-
time PCR were all purchased from Applied Biosys-
tems. PCR conditions, i.e. reaction mixture and
temperature profile, were according to the man-
ufacturer_s recommendations. The relative amount of
FECH mRNA was calculated as previously described
(Aurizi et al 2007).
Genotyping using microsatellite markers
Genotype analysis was conducted in the father of the
index patient using 10 microsatellite markers. These
markers are located in the genomic region of the
FECH gene in the order of cen-D18S69-D18S1152-
D18S41-D18S858 -FECH -D18S381-D18S977-
D18S1144-D18S1129-D18S1155-D18S64-qter in the
LDB map (Collins et al 1996). Fluorescence-labelled
PCR primers were synthesized with the available
sequence information. PCR was carried out using
standard conditions. Fragment length analysis was
performed on the ABI Prism 310 genetic analyser
(Applied Biosystems).
Results
Mutational analysis was initiated in the index patient.
Direct sequencing of PCR-amplified FECH gene
fragments identified a single nucleotide T deletion at
cDNA position 23 in the first exon (delT23). Frame-
shift, as the result of the deletion, generates a
premature stop codon at amino acid position 72. The
rest of the family members were screened specifically
for the delT23 mutation. The result showed that
besides the index patient, five other individuals
including her brother, her mother and all three of her
children also carried the mutation. No mutation was
Table 1 Clinical and biochemical data from the Israeli EPP family
Subjects Age
(years)
Photosensitivity Erythrocyte
protoporphyrin
(<80 mg/dl RBC)
Plasma
fluorescence
peak (mm)a
Faecal protoporphyrin
(<80 mg/g dry weight)
Mutation
delT23
SNP
IVS3-48c/t
Indexb 36 +++ 4917 188 680 Present c/t
Brotherb 26 +++ 6684 128 1072 Present c/t
Father 58 + 338 2 <80 Absent c/c
Mother 58 – 133 4 <80 Present t/t
Sister 33 – 70 None <80 Absent c/t
Eldest son 9 – 160 3 n.d. Present t/t
n.d.: not determined.
aHeight of the peak in the emission scan, observed at wavelengths 404 nm (excitation) and 635 nm (emission).
b Biochemical analyses were carried out at the time of diagnosis.
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found in the entire FECH gene of the patients_ father
by sequencing. Mutation delT23 was also absent in the
FECH gene of 50 non-porphyric Ashkenazi subjects.
SNP IVS3–48c/t was analysed among all the mem-
bers of the family. The segregation pattern between
mutation delT23 and SNP IVS3–48c/t within the family
is depicted in Fig. 1. Genotyping of SNP IVS3–48
among 50 non-porphyric Ashkenazi control subjects
identified 42 homozygotes IVS3–48t/t and 8 heterozy-
gotes IVS3–48c/t. The frequency of IVS3–48c is
therefore estimated as 8% in this population.
The father of the index patient was homozygous
IVS3–48c/c, a rare genotype in the general population.
The homozygosity was mostly likely due to the
parental consanguinity. Besides IVS3–48c/c, he was
homozygous for other intragenic SNPs including
IVS1–23t/t, 287G/G, 798C/C, 921G/G, IVS10–61g/g.
The results of microsatellite analysis extended the
homozygosity to a distance of at least 7.4 cM flanking
the FECH gene.
To test the presence of diploid FECH alleles in the
patients_ father, FECH mRNA was quantified by real-
time PCR and compared with that of control subjects
(genotypes t/t, c/t and c/c), as well as that of an EPP
patient from an unrelated family (genotype M/c). As
shown in Table 2, the relative amount of FECH
mRNA decreases in the order of t/t, c/t, c/c and M/c.
The value obtained from the father of the index
patient was 71% that of control 1 (genotype t/t), which
is comparable with 64% measured in control 3
(genotype c/c). However, control 3 was non-porphyric.
Discussion
EPP cases have been described in various populations.
The family of this study however, is the second
genetically tested EPP family ever reported in Israel
(Schoenfeld et al 2003). Extensive biochemical analy-
ses were conducted among members of this family
prior to genetic testing. The clinical and the biochem-
ical evidences, which included cutaneous photosensi-
tivity in combination with immense increases of
protoporphyrin concentration in erythrocytes as well
as presence of fluorescence peaks at 635 nm, was
sufficient to ascertain an EPP diagnosis in the index
patient and her brother. Interestingly, both of their
parents also presented with abnormal erythrocyte
protoporphyrin concentrations, i.e. a 4-fold increase
in the father and a 1.7-fold increase in the mother, and
measurable peaks in the plasma scan (Table 1). In
addition, the father was slightly photosensitive. These
findings raised the question whether EPP is recessive
in this family.
At the genetic level, the identification of a single
mutation delT23 and the characterization of SNP
IVS3–48c/t in the FECH gene proved the dominant
form of EPP in the family. As shown in Fig. 1, both
patients have an identical genotype of a mutated
FECH allele in trans to a low-expressed FECH allele
featuring IVS3–48c (M/c). This genotype, according to
Gouya et al, is required for the clinically overt EPP
which is the result of a reduction of the overall enzyme
activity below a critical threshold of õ35%, assuming
that the allele in which the frameshift mutation delT23
is resided will not produce any active enzyme (Gouya
et al 2006). The delT23 mutation apparently originated
from the patients_ mother. She, as well as three of her
grandchildren, had the genotype of a mutated allele in
trans to a normal FECH allele (M/t). According to the
current knowledge, these four individuals will remain
asymptomatic throughout their lives because of the
50% of normal amount of ferrochelatase enzyme they
possess.
A more complex situation was found in the patients_
father. Clinically, he presented with only a mild
Table 2 Levels of FECH mRNA in various individuals
Subjects SNP
IVS3-48c/t
Amount of normal FECH
transcript in relation to that
in control 1 (defined as 100%)
Control 1 t/t 100
Control 2 c/t 93
Control 3 c/c 64
Father of the
index patient
c/c 71
An unrelated
EPP patient
M/c 32
Table 3 Frequency of low-expressed FECH allele (IVS3–48c)
among different populations
Population Frequency Source
Japanese 45% Nakano et al (2006)
Chinese (Han) 41% Kong et al (2008)
Southeast Asian 31% Gouya et al (2006)
British 13% Berroeta et al (2007)
French 11% Gouya et al (2006)
Jewish
(Ashkenazi)
8% This study
Swiss 7% Schneider-Yin and Minder,
unpublished data
Spanish 5% Herrero et al (2007)
North African 3% Gouya et al (2006)
Italian 1% Aurizi et al (2007)
Black West Africa <1% Gouya et al (2006)
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photosensitivity. Biochemically, a substantial increase
in protoporphyrin concentration was repeatedly mea-
sured in erythrocytes. At the genetic level, no muta-
tions were identified in his FECH gene apart from the
homozygosity of IVS3–48c. His FECH mRNA was
71% of that of control 1 who has the genotype t/t.
The mild photosensitivity presented by the patients_
father could be attributed to the increased erythrocyte
protoporphyrin concentration, a phenomenon which
was shown in one of our previous studies (Cohen et al
2005). However, at the present time, the cause(s) of
increased protoporphyrin concentration in this partic-
ular individual is not fully understood. The FECH
gene, or IVS3–48c in that sense, is likely to play a role
in this setting. Although homozygous c/c alone might
not be sufficient, additional factors, genetic and
environmental alike, might act together to give rise
to the clinical and biochemical abnormalities in this
individual.
This study has shown that a combination of a
disabling FECH mutation with the hypomorphic
FECH IVS3–48c was the cause of EPP in two
members of the Jewish family. The 8% prevalence of
IVS3–48c in the Ashkenazi Jewish population is
similar to that found in the European populations
(Table 3). More importantly, this study presented the
first case of an individual with c/c genotype who had
both clinical and biochemical indications of EPP.
These observations suggest that IVS3–48c is a func-
tional variant of ferrochelatase and thus plays a role in
the pathogenesis of EPP.
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